Avelumab immune checkpoint inhibition

MSB0010718C - avelumab



Trial Studied treatment Control Patients Size Study type Results NCT

Lung cancer (metastatic) - immune checkpoint inhibition in all type of patients - immune checkpoint inhibition in second line - immune checkpoint inhibition in first line

JAVELIN Lung 200 ongoing avelumabdocetaxel2L, PDL1 positiveNA Confirmatory - NCT02395172
JAVELIN Lung 100 ongoing avelumabplatinum-based CT1L, PDL1 positiveNA Confirmatory - NCT02576574

Renal-cell carcinoma (advanced) - immune checkpoint inhibition in all type of patients

JAVELIN Renal 101 ongoing avelumab + axitinibsunitinib1L, PDL1 positiveNA Confirmatory - NCT02684006

Urothelial carcinoma (advanced) - immune checkpoint inhibition in all type of patients

JAVELIN Bladder 100 ongoing avelumabcontrolNA Confirmatory - NCT02603432